AI assistant
TherapeuticsMD, Inc. — Earnings Release 2015
Aug 6, 2015
35134_rns_2015-08-06_55a7f3a5-e2b8-42b3-bcca-dd0d67fe2bbc.zip
Earnings Release
Open in viewerOpens in your device viewer
8-K 1 txmd-8k_080615.htm CURRENT REPORT Field: Rule-Page
Field: /Rule-Page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 6, 2015
TherapeuticsMD, Inc.
(Exact Name of Registrant as Specified in its Charter)
| Nevada | 001-00100 | 87-0233535 |
|---|---|---|
| (State | ||
| or Other Jurisdiction | ||
| of Incorporation) | (Commission File | |
| Number) | (IRS Employer Identification No.) | |
| 6800 | ||
| Broken Sound Parkway NW, Third | ||
| Floor Boca | ||
| Raton, FL 33487 |
(Address of Principal Executive Office) (Zip Code)
Registrant’s telephone number, including area code: (561) 961-1900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2 below):
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| --- | --- |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Field: Page; Sequence: 1
Field: /Page
Item 2.02. Results of Operations and Financial Condition.
On August 6, 2015, TherapeuticsMD, Inc. issued a press release announcing its results of operations for its second fiscal quarter ended June 30, 2015. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
The information in this Current Report on Form 8-K (including the exhibit) is furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Current Report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit | |
|---|---|
| Number | Description |
| 99.1 | Press Release from TherapeuticsMD, Inc., dated August 6, 2015, |
| entitled “TherapeuticsMD Announces Second Quarter 2015 Financial Results.” |
Field: Page; Sequence: 2
Field: /Page
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 6, 2015 | THERAPEUTICSMD, INC. |
|---|---|
| By: | /s/ Daniel A. Cartwright |
| Name: | Daniel A. Cartwright |
| Title: | Chief Financial Officer |
Field: Page; Sequence: 3
Field: /Page
EXHIBIT INDEX
| Exhibit | |
|---|---|
| Number | Description |
| 99.1 | Press Release from TherapeuticsMD, Inc., dated August 6, 2015, entitled “TherapeuticsMD Announces Second Quarter 2015 Financial Results.” |
Field: Page; Sequence: 4; Options: Last
Field: /Page